Recent studies have initially shown that MRI-based rim enhancement associates with poor prognosis in hepatocellular carcinoma (HCC) patients, but their sample sizes are small, leading to a necessary of comprehensive analyses to make a relatively solid statement. Thus, this meta-analysis aimed to summarize the correlation between MRI-based rim enhancement and prognosis in HCC patients. Until March 2023, a literature search was conducted on Web of Science, PubMed, EMBASE, Cochrane, CNKI, Wangfang, and CQVIP databases in order to identify studies that report the correlation between MRI-based rim enhancement and the prognosis of HCC patients. MRI-based rim enhancement and prognostic data were extracted and analyzed. In our study, eight studies containing 1816 HCC patients were analyzed. Generally, the presence of MRI-based rim enhancement was related to shortened disease-free survival (DFS) [hazard ratio (HR): 2.77, 95% confidence interval (CI): 2.11-3.62, P < 0.001], and worse overall survival (OS) (HR: 5.43, 95% CI: 2.14-13.79, P < 0.001). While no other prognostic data could be retrieved. Funnel plots, Begg's test, and Egger's test all indicated that no publication bias existed; and the risk score by Newcastle-Ottawa Scale criteria ranged from 7-9 points, suggesting a generally low risk of bias. Meanwhile, the sensitivity analysis showed that the significant findings did not change by omitting each study. Then, subgroup analyses revealed that no matter stratified by tumor size, treatment option, or sample size, rim enhancement was linked with unsatisfied DFS (all P < 0.05). Conclusively, MRI-based rim enhancement could effectually estimate poor survival in HCC patients, indicating its good prognostic value.

中文翻译：

---

基于磁共振成像的边缘增强可以有效预测肝细胞癌的不良预后：一项荟萃分析。

最近的研究初步表明，基于 MRI 的边缘增强与肝细胞癌 (HCC) 患者的不良预后相关，但其样本量较小，因此需要进行全面分析才能做出相对可靠的陈述。因此，本荟萃分析旨在总结基于 MRI 的边缘增强与 HCC 患者预后之间的相关性。截至2023年3月，我们在Web of Science、PubMed、EMBASE、Cochrane、CNKI、万方和CQVIP数据库上进行了文献检索，以识别报告基于MRI的边缘增强与HCC患者预后之间相关性的研究。提取并分析基于 MRI 的边缘增强和预后数据。在我们的研究中，分析了包含 1816 名 HCC 患者的八项研究。一般来说，基于 MRI 的边缘增强与无病生存期 (DFS) 缩短有关 [风险比 (HR)：2.77，95% 置信区间 (CI)：2.11-3.62，P < 0.001]，并且总体情况更差生存率（OS）（HR：5.43，95% CI：2.14-13.79，P < 0.001）。虽然无法检索到其他预测数据。漏斗图、Begg检验和Egger检验均表明不存在发表偏倚；纽卡斯尔-渥太华量表标准的风险评分范围为 7-9 分，表明偏倚风险普遍较低。同时，敏感性分析表明，省略每项研究后，显着的发现并没有改变。然后，亚组分析显示，无论按肿瘤大小、治疗方案或样本大小进行分层，边缘增强均与不满意的 DFS 相关（所有 P < 0.05）。总之，基于 MRI 的边缘增强可以有效估计 HCC 患者的不良生存率，表明其具有良好的预后价值。